Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.
lymphocyte subsets
minimal change disease
steroid dependence
Journal
Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
07
06
2018
revised:
21
08
2018
accepted:
30
08
2018
pubmed:
1
12
2018
medline:
20
8
2019
entrez:
1
12
2018
Statut:
ppublish
Résumé
Both levamisole and mycophenolate mofetil (MMF) prevent relapses in patients with frequently relapsing nephrotic syndrome; however, their efficacy has not been compared prospectively. This single-center, randomized, open-label trial enrolled 149 children ages 6-18 years with frequently relapsing or steroid-dependent nephrotic syndrome. Participants were randomized in a 1:1 ratio to receive therapy with MMF (750-1000 mg/m
Identifiants
pubmed: 30497684
pii: S0085-2538(18)30646-X
doi: 10.1016/j.kint.2018.08.039
pii:
doi:
Substances chimiques
Glucocorticoids
0
Immunosuppressive Agents
0
Levamisole
2880D3468G
Mycophenolic Acid
HU9DX48N0T
Banques de données
CTRI
['CTRI/2012/02/002394']
Types de publication
Comparative Study
Equivalence Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
210-218Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2018 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.